Quick Answer
Calidi Biotherapeutics, Inc. reported Net Income of -$19.91 million for fiscal year 2025.
Calidi Biotherapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$19.91M | +10.1% |
| 2024 | -$22.14M | +24.2% |
| 2023 | -$29.22M | -14.9% |
| 2022 | -$25.43M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.15M | -1.9% | +9.9% |
| June 30, 2025 | -$5.71M | +0.9% | -12.9% |
| March 31, 2025 | -$5.06M | +29.9% | -0.2% |
| September 30, 2024 | -$5.05M | -149.7% | +12.4% |
| June 30, 2024 | -$5.77M | +53.9% | +20.2% |
| March 31, 2024 | -$7.22M | -11.8% | -257.0% |
| September 30, 2023 | -$2.02M | +62.2% | +83.8% |
| June 30, 2023 | -$12.50M | -173.2% | -93.5% |
- Calidi Biotherapeutics, Inc. showed an increase of +10.1% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Calidi Biotherapeutics, Inc.’s net income has grown by 21.7% (from -$25.43 million to -$19.91 million).
- The most recent figure is from Calidi Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: